AVALO THERAPEUTICS, INC. Earnings Per Share (Basic)
AVALO THERAPEUTICS, INC. (AVTX) reported Earnings Per Share (Basic) of -$0.83 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.83.
- AVALO THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.98.
- AVALO THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$2.19, a 323.47% decline year-over-year.
- AVALO THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$1.92, a 145.61% decline year-over-year.
- AVALO THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$5.84.
- AVALO THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$7.94.
- AVALO THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$113.58.
- AVALO THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$1063.00.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.83 10-Q · filed 2026-08-06 | -$1.75 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | -$0.98 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | -$5.84 10-K · filed 2026-03-23 | |||||||
| 2025-09-30 | -$2.19 10-Q · filed 2025-11-06 | -$4.14 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$5.47 10-Q · filed 2025-11-06 | -$8.75 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$1.92 10-Q · filed 2026-08-06 | -$3.18 10-Q · filed 2026-08-06 | -$6.56 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$6.85 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | -$1.25 10-Q · filed 2026-05-13 | -$4.66 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$4.89 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$5.63 derived: net income ÷ weighted average shares · filed 2026-05-13 | ||||
| 2024-12-31 | -$3.44 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$3.76 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$4.52 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$7.94 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $0.98 10-Q · filed 2025-11-06 | $2.98 derived: net income ÷ weighted average shares · filed 2025-11-06 | $0.01 10-Q · filed 2025-11-06 | -$58.03 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||||
| 2024-06-30 | $4.21 10-Q · filed 2025-08-07 | -$24.11 10-Q · filed 2025-08-07 | -$138.96 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$180.03 derived: net income ÷ weighted average shares · filed 2025-08-07 | ||||
| 2024-03-31 | -$141.14 10-Q · filed 2025-05-12 | -$141.00 10-Q · filed 2024-05-13 | -$155.34 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$217.05 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$297.69 derived: net income ÷ weighted average shares · filed 2025-05-12 | |||
| 2023-12-31 | -$10.12 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$26.73 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$61.07 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$113.58 10-K · filed 2025-03-20 | -$114.00 10-K · filed 2024-03-29 | |||
| 2023-09-30 | -$26.83 10-Q · filed 2024-11-07 | -$0.11 10-Q · filed 2023-11-09 | -$106.07 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$231.05 10-Q · filed 2024-11-07 | -$0.96 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | -$140.73 10-Q · filed 2024-08-12 | -$0.59 10-Q · filed 2023-08-03 | -$338.85 10-Q · filed 2024-08-12 | -$1.41 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | -$204.00 10-Q/A · filed 2024-07-11 | -$0.85 10-Q · filed 2023-05-04 | ||||||
| 2022-12-31 | -$1063.00 10-K · filed 2024-03-29 | -$4.43 10-K · filed 2023-03-29 | ||||||
| 2022-09-30 | $0.34 10-Q · filed 2023-11-09 | -$3.39 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | -$1.38 10-Q · filed 2023-08-03 | -$3.73 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | -$2.35 10-Q · filed 2023-05-04 | |||||||
| 2018-12-31 | -$1.20 10-K · filed 2019-03-18 | |||||||
| 2017-12-31 | -$0.11 10-K · filed 2018-04-02 | $0.46 derived: net income ÷ weighted average shares · filed 2019-03-18 | $0.42 10-K · filed 2019-03-18 | |||||
| 2017-09-30 | $0.52 10-K · filed 2018-04-02 | $0.65 10-Q · filed 2017-11-07 | ||||||
| 2017-06-30 | -$0.14 10-K · filed 2018-04-02 | |||||||
| 2017-03-31 | -$0.19 10-K · filed 2018-04-02 | |||||||
| 2016-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$0.87 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$1.87 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | -$0.70 10-Q · filed 2017-11-07 | -$1.71 10-Q · filed 2017-11-07 | ||||||
| 2015-12-31 | -$4.71 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |